Last reviewed · How we verify
bimatoprost formulation A solution
Bimatoprost is a prostaglandin analog that mimics the action of prostaglandin F2-alpha, leading to increased uveoscleral outflow and reduced intraocular pressure.
Bimatoprost is a prostaglandin analog that mimics the action of prostaglandin F2-alpha, leading to increased uveoscleral outflow and reduced intraocular pressure. Used for Glaucoma, Ocular hypertension.
At a glance
| Generic name | bimatoprost formulation A solution |
|---|---|
| Sponsor | Allergan |
| Drug class | Prostaglandin analog |
| Target | Prostaglandin F2-alpha receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Bimatoprost works by binding to the prostaglandin F2-alpha receptor, which leads to the relaxation of the uveoscleral tissue and increased outflow of aqueous humor, resulting in decreased intraocular pressure. This mechanism is similar to other prostaglandin analogs, such as latanoprost and travoprost.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Eyelash growth
- Iris pigmentation changes
- Periorbital erythema
Key clinical trials
- Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension (PHASE1, PHASE2)
- Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA) (PHASE1)
- Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia (PHASE1)
- A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma (PHASE3)
- Bimatoprost in the Treatment of Eyelash Hypotrichosis (PHASE3)
- Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia (PHASE2)
- Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss (PHASE2)
- Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |